EA200970131A1 - Миметические антитела для glp-1 человека, композиции, способы и применения - Google Patents

Миметические антитела для glp-1 человека, композиции, способы и применения

Info

Publication number
EA200970131A1
EA200970131A1 EA200970131A EA200970131A EA200970131A1 EA 200970131 A1 EA200970131 A1 EA 200970131A1 EA 200970131 A EA200970131 A EA 200970131A EA 200970131 A EA200970131 A EA 200970131A EA 200970131 A1 EA200970131 A1 EA 200970131A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
human glp
compositions
mimetical
antibodies
Prior art date
Application number
EA200970131A
Other languages
English (en)
Inventor
Кэрин Т. О'Нил
Кристен Пича
Original Assignee
Сентокор, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентокор, Инк. filed Critical Сентокор, Инк.
Publication of EA200970131A1 publication Critical patent/EA200970131A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Настоящее изобретение относится по меньшей мере к одному улучшенному миметическому антителу для GLP-1 человека или к определенному участку или варианту, включающему выделенные нуклеиновые кислоты, которые кодируют по меньшей мере одно миметическое антитело или определенный участок или варианты, относится к векторам, клеткам-хозяевам, трансгенным животным или растениям и способам их получения и применения, включающим терапевтические композиции, способы и средства.
EA200970131A 2006-07-18 2007-07-18 Миметические антитела для glp-1 человека, композиции, способы и применения EA200970131A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83170406P 2006-07-18 2006-07-18
PCT/US2007/073752 WO2008011446A2 (en) 2006-07-18 2007-07-18 Human glp-1 mimetibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
EA200970131A1 true EA200970131A1 (ru) 2009-08-28

Family

ID=38596585

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970131A EA200970131A1 (ru) 2006-07-18 2007-07-18 Миметические антитела для glp-1 человека, композиции, способы и применения

Country Status (18)

Country Link
US (2) US20090325873A1 (ru)
EP (1) EP2049567A2 (ru)
JP (1) JP2010500868A (ru)
KR (1) KR20090039787A (ru)
CN (1) CN101535341A (ru)
AR (1) AR061930A1 (ru)
AU (1) AU2007275294A1 (ru)
BR (1) BRPI0714334A2 (ru)
CA (1) CA2658286A1 (ru)
CR (1) CR10619A (ru)
EA (1) EA200970131A1 (ru)
EC (1) ECSP099079A (ru)
MX (1) MX2009000748A (ru)
NO (1) NO20090780L (ru)
TW (1) TW200821386A (ru)
UY (1) UY30494A1 (ru)
WO (1) WO2008011446A2 (ru)
ZA (1) ZA200901132B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
EP2207808B1 (en) 2007-11-02 2013-05-08 Novartis AG Improved nogo-a binding molecules and pharmaceutical use thereof
EP2298801A4 (en) * 2008-06-17 2011-08-03 Otsuka Chemical Co Ltd GLYCOSYLATED GLP-1 PEPTIDE
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
EP2373681B1 (en) 2008-12-10 2017-01-18 Glaxosmithkline LLC Pharmaceutical compositions of albiglutide
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
SG176000A1 (en) * 2009-05-13 2011-12-29 Protein Delivery Solutions Llc Pharmaceutical system for trans-membrane delivery
CN102595897A (zh) 2009-09-02 2012-07-18 默沙东公司 作为用于糖尿病的治疗或预防的二肽基肽酶-iv抑制剂的氨基四氢吡喃
EP2538783B1 (en) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2011130533A1 (en) 2010-04-16 2011-10-20 Centocor Ortho Biotech Inc. Engineered plant cysteine proteases and their uses
EP2566502A4 (en) * 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
US20150057220A1 (en) 2012-04-16 2015-02-26 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
CN103204944B (zh) * 2013-03-26 2014-05-28 江苏健德生物药业有限公司 用于治疗糖尿病的长效免疫融合蛋白
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
WO2019036859A1 (zh) * 2017-08-21 2019-02-28 中国科学院动物研究所 分泌glp-1及其衍生物的蛋白表达系统及其制备方法和用途
TWI783890B (zh) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
TWI639987B (zh) * 2017-10-11 2018-11-01 奇美醫療財團法人奇美醫院 具有位置感知的穿刺輔助教學裝置
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CR20210193A (es) 2018-10-22 2021-06-15 Janssen Pharmaceutica Nv Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas
KR20220143037A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 Glp-1 조성물 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
US6849719B2 (en) * 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
JP2000319297A (ja) * 1999-03-30 2000-11-21 Noguchi Inst 酵素的に安定な複合糖ペプチドの調製法
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
ATE346093T1 (de) * 2000-06-16 2006-12-15 Lilly Co Eli Analoge des glucagon ähnlichen peptid-1
CA2434237C (en) * 2000-12-07 2012-05-15 Eli Lilly And Company Glp-1 fusion proteins
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
EP1575499A2 (en) * 2002-06-28 2005-09-21 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
AU2003272970B2 (en) * 2002-10-11 2009-05-28 Sanwa Kagaku Kenkyusho Co. Ltd. GLP-1 derivatives and transmicosal absorption preparations thereof
EP1644416A4 (en) 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
MXPA06011425A (es) 2004-03-31 2007-03-12 Johnson & Johnson Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.

Also Published As

Publication number Publication date
CA2658286A1 (en) 2008-01-24
ECSP099079A (es) 2009-02-27
UY30494A1 (es) 2008-01-31
CN101535341A (zh) 2009-09-16
US8071103B2 (en) 2011-12-06
JP2010500868A (ja) 2010-01-14
CR10619A (es) 2009-06-04
KR20090039787A (ko) 2009-04-22
WO2008011446A3 (en) 2008-09-18
AR061930A1 (es) 2008-10-01
WO2008011446A2 (en) 2008-01-24
MX2009000748A (es) 2009-03-31
US20080044411A1 (en) 2008-02-21
AU2007275294A1 (en) 2008-01-24
US20090325873A1 (en) 2009-12-31
BRPI0714334A2 (pt) 2013-05-14
EP2049567A2 (en) 2009-04-22
ZA200901132B (en) 2010-10-27
TW200821386A (en) 2008-05-16
NO20090780L (no) 2009-04-03

Similar Documents

Publication Publication Date Title
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
EA200701362A1 (ru) Агонисты glp-1, композиции, способы и применения
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
BRPI0921665A2 (pt) humanizado anti-il-6 anticorpos
EA201070479A1 (ru) Человеческие антиамилоидные антитела, композиции, способы и их применение
WO2006085961A3 (en) Anti-mcp-1 antibodies, compositions, methods and uses
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
UA108066C2 (uk) Білки, що зв'язуються з cgrp-рецепторами людини
WO2006124451A3 (en) Anti-il-13 antibodies, compositions, methods and uses
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA200600126A1 (ru) Антитела против tnf, композиции, способы и применения
AR053456A1 (es) Anticuerpos de p- caderina
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
MX2007011975A (es) Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos.
WO2008048871A3 (en) Cynomolgus il-13 mutein proteins, antibodies, compositions, methods and uses
UY29552A1 (es) Anticuerpos anti-mcp-1, composiciones, métodos y usos
GT200600212A (es) Anticuerpos anti-mcp-1, composiciones, metodos y usos
UY29509A1 (es) Anticuerpos anti-il-6, composiciones, métodos y usos